دورية أكاديمية
International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline 18 F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation.
| العنوان: | International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline 18 F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation. |
|---|---|
| المؤلفون: | Boellaard R; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam, The Netherlands; r.boellaard@amsterdamumc.nl., Buvat I; LITO, Inserm, Institut Curie, Orsay, France., Nioche C; LITO, Inserm, Institut Curie, Orsay, France., Ceriani L; Clinic of Nuclear Medicine and PET-CT Centre, Imaging Institute of Southern Switzerland; and EOC, Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona, Switzerland., Cottereau AS; Department of Nuclear Medicine, Cochin Hospital, APHP; and Faculté de Médecine, Université Paris Cité, Paris, France., Guerra L; Nuclear Medicine Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.; School of Medicine and Surgery, University of Milano Bicocca, Milan, Italy., Hicks RJ; Department of Medicine, St. Vincent's Hospital Medical School, University of Melbourne, Melbourne, Victoria, Australia., Kanoun S; Centre de Recherche Clinique de Toulouse, Team 9, Toulouse, France., Kobe C; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Loft A; PET & Cyclotron Unit 3982, Copenhagen University Hospital, Copenhagen, Denmark., Schöder H; Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York., Versari A; Nuclear Medicine Department, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy., Voltin CA; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Zwezerijnen GJC; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam, The Netherlands., Zijlstra JM; Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam, The Netherlands., Mikhaeel NG; Department of Clinical Oncology, Guy's Cancer Centre and School of Cancer and Pharmaceutical Sciences, King's College London University, London, United Kingdom., Gallamini A; Research and Innovation Department, Antoine Lacassagne Cancer Center, Nice, France., El-Galaly TC; Department of Hematology, Aalborg University Hospital, Aalborg, Denmark.; Department of Hematology, Odense University Hospital, Odense, Denmark., Hanoun C; Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Chauvie S; Medical Physics Division, Santa Croce e Carle Hospital, Cuneo, Italy., Ricci R; LYSARC, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France., Zucca E; Oncology Institute of Southern Switzerland; and EOC, Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona, Switzerland; and., Meignan M; Department of Nuclear Medicine, Cochin Hospital, APHP; and Faculté de Médecine, Université Paris Cité, Paris, France., Barrington SF; King's College London and Guy's and St. Thomas's PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom. |
| المصدر: | Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2024 Aug 01. Date of Electronic Publication: 2024 Aug 01. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Reston, VA : Society of Nuclear Medicine Original Publication: [Chicago, Ill.] : S.N. Turiel & Assoc. |
| مستخلص: | Total metabolic tumor volume (TMTV) is prognostic in lymphoma. However, cutoff values for risk stratification vary markedly, according to the tumor delineation method used. We aimed to create a standardized TMTV benchmark dataset allowing TMTV to be tested and applied as a reproducible biomarker. Methods: Sixty baseline 18 F-FDG PET/CT scans were identified with a range of disease distributions (20 follicular, 20 Hodgkin, and 20 diffuse large B-cell lymphoma). TMTV was measured by 12 nuclear medicine experts, each analyzing 20 cases split across subtypes, with each case processed by 3-4 readers. LIFEx or ACCURATE software was chosen according to reader preference. Analysis was performed stepwise: TMTV1 with automated preselection of lesions using an SUV of at least 4 and a volume of at least 3 cm 3 with single-click removal of physiologic uptake; TMTV2 with additional removal of reactive bone marrow and spleen with single clicks; TMTV3 with manual editing to remove other physiologic uptake, if required; and TMTV4 with optional addition of lesions using mouse clicks with an SUV of at least 4 (no volume threshold). Results: The final TMTV (TMTV4) ranged from 8 to 2,288 cm 3 , showing excellent agreement among all readers in 87% of cases (52/60) with a difference of less than 10% or less than 10 cm 3 In 70% of the cases, TMTV4 equaled TMTV1, requiring no additional reader interaction. Differences in the TMTV4 were exclusively related to reader interpretation of lesion inclusion or physiologic high-uptake region removal, not to the choice of software. For 5 cases, large TMTV differences (>25%) were due to disagreement about inclusion of diffuse splenic uptake. Conclusion: The proposed segmentation method enabled highly reproducible TMTV measurements, with minimal reader interaction in 70% of the patients. The inclusion or exclusion of diffuse splenic uptake requires definition of specific criteria according to lymphoma subtype. The publicly available proposed benchmark allows comparison of study results and could serve as a reference to test improvements using other segmentation approaches. (© 2024 by the Society of Nuclear Medicine and Molecular Imaging.) |
| فهرسة مساهمة: | Keywords: 18F-FDG PET/CT; benchmark; lymphoma; total metabolic tumor volume |
| تواريخ الأحداث: | Date Created: 20240801 Latest Revision: 20240801 |
| رمز التحديث: | 20240802 |
| DOI: | 10.2967/jnumed.124.267789 |
| PMID: | 39089812 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1535-5667 |
|---|---|
| DOI: | 10.2967/jnumed.124.267789 |